idov-safe
Biologicalexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2024 (NCT06346041)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusSupplementation
Oncolytic virus supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06718946 | Early Phase 1 (Phase 1) | Dec 10, 2024 | Fudan University |
| NCT06380309 | Early Phase 1 (Phase 1) | May 6, 2024 | Peking University |
| NCT06346041 | Early Phase 1 (Phase 1) | Apr 12, 2024 | Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1